Results 1 to 10 of about 10,090 (144)

Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention [PDF]

Microbiology Spectrum
In Tuberculosis Trials Consortium Study 35, which investigated the optimal dosing and safety of once-weekly isoniazid and rifapentine (3HP) in 69 children requiring tuberculosis preventive therapy, 7 children with HIV received 50 mg of once-daily ...
Ruvarashe J. Madzime, Louvina van der Laan, Samantha du Toit, Shaun Barnabas, Ingrid Courtney, Nicole E. Brown, Rada Savic, Belen P. Solans, Meredith G. Dixon, Lufina Tsirizani, Paolo Denti, Rosanna Boyd, Anneke C. Hesseling   +12 more
doaj   +2 more sources

Perceptions of dolutegravir-based regimen use among people living with HIV in Limpopo province: A qualitative study [PDF]

Curationis
Background: HIV and AIDS continues to be a critical public health challenge, with sub-Saharan Africa shouldering the heaviest burden. Progress towards disease management has been implemented over the years, and antiretroviral therapy (ART) has been the ...
Zandile R. Sibeko, Boitumelo J. Molato, Salaminah S.P. Moloko-Phiri   +2 more
doaj   +2 more sources

Dolutegravir use is related to lower HTLV-1 proviral load in people co-infected by HIV-1 [PDF]

Communications Medicine
Background Infection by human T-cell lymphotropic virus type 1 (HTLV-1) affects millions of people worldwide and causes severe diseases. To date, no specific treatment is available for HTLV infection. The purpose of this study was to determine the impact
Tatiana Fernandez, María B. Arriaga, Rafaela Mayoral, Eduardo M. Netto, Carlos Brites   +4 more
doaj   +2 more sources

Dolutegravir-associated hyperglycemia: a narrative review [PDF]

AIDS Research and Therapy
Dolutegravir is a preferred antiretroviral drug given its high resistance barrier and efficacy; however, reports from sub-Saharan Africa indicate increased hyperglycemia rates among individuals living with HIV on dolutegravir.
Allan Buzibye, Barbara Castelnuovo, Robert C. Bollinger, Joseph Ssebulime, Denis Omali, Daniel Muller, Frank Mulindwa, Eva Laker, Catriona Waitt, Irene Andia, Mohammed Lamorde, Ahmet Hoke, Bernard S. Bagaya, Yukari C. Manabe   +13 more
doaj   +2 more sources

Prevalence and Correlates of Hyperglycemia Among People Living With HIV and TB on Dolutegravir‐Based Antiretroviral Therapy in Zimbabwe: A Cross‐Sectional Study [PDF]

Health Science Reports
Background and Aims In low‐ and middle‐income countries, dolutegravir‐based antiretroviral therapy regimens are the preferred first‐line treatment for adults, adolescents, and children with human immunodeficiency virus (HIV).
Tafadzwa Zireva, Cuthbert Musarurwa, Arthur Mazhandu, Brenda Nherera, Shungu Munyati, Justen Manasa, Danai Tavonga Zhou, Donald Vhanda   +7 more
doaj   +2 more sources

Acute interstitial nephritis due to dolutegravir: The first case reported

Nefrología, 2023
Kidney disease is frequent in HIV-patients. We present a case of a 44-year-old woman, with known uncontrolled HIV infection and chronic kidney disease due to HIV-associated nephropathy.
Rui Barata, Bernardo Marques da Costa, David Navarro, Marco Mendes, Cecília Silva, Mário Góis, Helena Sousa, Fernando Nolasco   +7 more
doaj   +3 more sources

Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Viruses, 2023
Millions of Africans are on dolutegravir-based antiretroviral therapy (ART), but few detailed descriptions of dolutegravir resistance and its clinical management exist.
Hope Kanise, Joep J. van Oosterhout, Pachawo Bisani, John Songo, Bilaal W. Matola, Chifundo Chipungu, Katherine Simon, Carrie Cox, Mina C. Hosseinipour, Jean-Batiste Sagno, Risa M. Hoffman, Claudia Wallrauch, Sam Phiri, Kim Steegen, Andreas Jahn, Rose Nyirenda, Tom Heller   +16 more
doaj   +1 more source

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

Southern African Journal of HIV Medicine, 2022
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women.
Enkosi Mondleki, Clifford G. Banda, Nomathemba C. Chandiwana, Simiso Sokhela, Lubbe Wiesner, Francois Venter, Gary Maartens, Phumla Z. Sinxadi   +7 more
doaj   +1 more source

Dolutegravir [PDF]

Hospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Levien, Terri L, Baker, Danial E   +2 more
openaire   +3 more sources

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Metabolites, 2022
Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir
Jessica Cusato, Alberto Borghetti, Elisabetta Teti, Maurizio Milesi, Maria Cristina Tettoni, Stefano Bonora, Mattia Trunfio, Antonio D’Avolio, Mirko Compagno, Simona Di Giambenedetto, Giovanni Di Perri, Andrea Calcagno   +11 more
doaj   +1 more source